Jonathan A. Ledermann
Impact in
- Reproductive Medicine top 0.02%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.1%
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
Papers in
-
- Ovarian cancer diagnosis and treatment 158
- Oncology 144
- PARP inhibition in cancer therapy 105
- Co-authors
- Gordon C. Jayson (20 shared papers)Elise C. Kohn (5 shared papers)Henry C Kitchener (7 shared papers)Nicoletta Colombo (42 shared papers)Antonio González-Martı́n (24 shared papers)Michael Friedländer (29 shared papers)Gordon Rustin (30 shared papers)Philipp Harter (19 shared papers)
- Journals
- Journal of Clinical Oncology (60 papers)International Journal of Gynecological Cancer (44 papers)Annals of Oncology (43 papers)Gynecologic Oncology (21 papers)European Journal of Cancer (12 papers)
- Partner nations
- United KingdomUnited StatesCanada
In The Last Decade
Jonathan A. Ledermann
288 papers receiving 17.5k citations
Jonathan A. Ledermann's Hit Papers
Peers
Comparison fields: 5 of 142
- Reproductive Medicine 5.9k
- Oncology 7.5k
- Obstetrics and Gynecology 2.0k
- Hepatology 917
- Cancer Research 1.7k
Countries citing papers authored by Jonathan A. Ledermann
This map shows the geographic impact of Jonathan A. Ledermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan A. Ledermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan A. Ledermann more than expected).
Fields of papers citing papers by Jonathan A. Ledermann
This network shows the impact of papers produced by Jonathan A. Ledermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan A. Ledermann. The network helps show where Jonathan A. Ledermann may publish in the future.
Co-authors
The 25 scholars most cited alongside Jonathan A. Ledermann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 297 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ovarian cancer Hit paper breakdown → | 2014 | 1439 |
| 2 | Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer Hit paper breakdown → | 2012 | 1363 |
| 3 | Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Hit paper breakdown → | 2014 | 1066 |
| 4 | Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Hit paper breakdown → | 2003 | 887 |
| 5 | Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2013 | 804 |
| 6 | ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer Hit paper breakdown → | 2015 | 565 |
| 7 | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial Hit paper breakdown → | 2013 | 472 |
| 8 | Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial Hit paper breakdown → | 2017 | 422 |
| 9 | 2007 | 408 | |
| 10 | Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2022 | 331 |
| 11 | 2011 | 316 | |
| 12 | 2016 | 309 | |
| 13 | 2012 | 285 | |
| 14 | 2020 | 279 | |
| 15 | ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease Hit paper breakdown → | 2019 | 273 |
| 16 | 2013 | 270 | |
| 17 | Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments Hit paper breakdown → | 2015 | 264 |
| 18 | 2016 | 198 | |
| 19 | 2014 | 197 | |
| 20 | 2003 | 182 |
About Jonathan A. Ledermann
Jonathan A. Ledermann is a scholar working on Reproductive Medicine, Oncology, Genetics, Obstetrics and Gynecology and Surgery, having authored 297 papers that have together received 17.7k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (158 papers), PARP inhibition in cancer therapy (105 papers), Endometrial and Cervical Cancer Treatments (39 papers), BRCA gene mutations in cancer (37 papers), Intraperitoneal and Appendiceal Malignancies (23 papers), Renal cell carcinoma treatment (16 papers), Cancer Genomics and Diagnostics (15 papers) and Cancer Mechanisms and Therapy (11 papers). The work is most often cited by research in Reproductive Medicine (5.9k citations), Oncology (7.5k citations), Obstetrics and Gynecology (2.0k citations), Hepatology (917 citations) and Cancer Research (1.7k citations). Jonathan A. Ledermann has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Gordon C. Jayson, Elise C. Kohn, Henry C Kitchener, Nicoletta Colombo, Antonio González-Martı́n, Michael Friedländer, Gordon Rustin, Philipp Harter, Charlie Gourley and Ignace Vergote. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Gynecological Cancer, Annals of Oncology, Gynecologic Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.